Showing 5201-5210 of 8729 results for "".
- Analysis of Dermatology Mobile Apps with AI Capability Reveals Weaknesses, Transparency Concernshttps://practicaldermatology.com/news/analysis-of-dermatology-mobile-apps-reveals-weaknesses-transparency-concerns/2462434/A new analysis of dermatology mobile applications (apps) revealed transparency, validation, and accuracy concerns. "With advancements in mobile technology and artificial intelligence (AI) methods, there has been a substantial surge in the availability of direct-to-consumer mobile applicat
- INTEGUMENT-PED: Roflumilast Cream 0.05% Effective at Improving AD in Childrenhttps://practicaldermatology.com/news/integument-ped-roflumilast-cream-005-effective-at-improving-ad-in-children/2462429/New data from a pivotal phase 3 trial indicates roflumilast cream 0.05% is associated with significantly improved atopic dermatitis (AD) in children 2 to 5 years of age with mild-to-moderate AD. Researchers for the Interventional Trial Evaluating Roflumilast Cream for the Treatment of Ato
- Lebrikizumab Linked with Improvement in Patients with AD and Skin of Colorhttps://practicaldermatology.com/news/lebrikizumab-linked-with-improvement-in-patients-with-atopic-dermatitis-and-skin-of-color/2462431/New first-of-its-kind research presented at the American Academy of Dermatology 2024 Annual Meeting suggests that lebrikizumab showed efficacy in patients with skin of color who had atopic dermatitis (AD). “People with skin of color are disproportionately affected by AD, often experienci
- Analysis: Alopecia Areata Linked with Work Productivity Losseshttps://practicaldermatology.com/news/analysis-alopecia-areata-linked-with-work-productivity-losses/2462430/Results from a new real-world analysis illuminated demographic and clinical characteristics associated with productivity losses in individuals with alopecia areata. “Patients with alopecia areata experience poor health-related quality of life and significant disease burden,” the authors w
- Study: Seborrheic Dermatitis Has Distinct Molecular Signaturehttps://practicaldermatology.com/news/study-seborrheic-dermatitis-has-distinct-molecular-signature/2462428/Newly unveiled research suggests that seborrheic dermatitis has its own unique molecular signature and is distinct in its own disease-specific pattern. “The pathophysiology of seborrheic dermatitis has been poorly understood. We sought to understand the gene expression patterns in seborrh
- Ruxolitinib Cream 1.5% Effective in Hidradenitis Suppurativa Hurley Stage 1 or 2 Patientshttps://practicaldermatology.com/news/ruxolitinib-cream-15-shows-efficacy-for-hidradenitis-suppurativa-hurley-stage-1-or-2-patients/2462427/Data from a new phase 2 trial indicate twice-daily ruxolitinib cream, 1.5% (OpzeluraTM, Incyte) in adult patients with Hurley stage 1 or 2 (mild-to-moderate) hidradenitis suppurativa (HS) was safe and effective. The primary endpoint of the study was achieved, with patients on t
- Alumis Closes $259 Million Financing to Help Launch Phase 3 Psoriasis Trial for Lead Asset ESK-001https://practicaldermatology.com/news/alumis-closes-259-million-financing-to-help-launch-phase-3-psoriasis-trial-for-lead-asset/2462267/In this year's largest privite biotech fundraise to date, Alumis announced $259 million Series C financing to initiate pivotal phase 3 clinical trials for its lead candidate ESK-001, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe pl
- ADORING Trials: Tapinarof Cream, 1% Effective in Patients with Skin of Colorhttps://practicaldermatology.com/news/adoring-trials-tapinarof-effective-in-patients-with-skin-of-color/2462266/In a patient population with diverse skin tones, tapinarof cream, 1% (VTAMA®, Dermavant) was shown to have significant efficacy in both adults and children as young as 2 years of age with atopic dermatitis (AD), according to new results presented at the 2024 American Academy of Dermatology Annual
- Thermo Fisher Scientific Launches CorEvitas Clinical Registry in Generalized Pustular Psoriasishttps://practicaldermatology.com/news/thermo-fisher-scientific-launches-corevitas-clinical-registry-in-generalized-pustular-psoriasis/2462265/Thermo Fisher Scientific announced the launch of a new CorEvitas syndicated clinical registry in generalized pustular psoriasis (GPP). This registry, which is open to enrollment, is CorEvitas’ 10th syndicated disease registry and addresses an unmet need for real-world evidence (RW
- Long-acting Reversible Contraception Linked with Acne Young Adults: Analysishttps://practicaldermatology.com/news/relationship-between-long-acting-reversible-contraception-and-acne-in-a-cohort-of-adolescents-and-young-adults/2462264/The use of progestin-only long-acting reversible contraception (LARC) may have an increased risk of developing acne or experiencing worsening of acne symptoms, a new analysis indicates. "Few studies have focused primarily on the effects of hormonal LARC on the developmen